Funds for the share repurchase program will be supported by our strong cash flow from operations, financial flexibility from our recent debt refinancing and strength of our asset base." (See Tivity Health stock chart on TipRanks) Last month, Truist Financial analyst David S Macdonald reiterated a Hold rating on the stock. The analyst, however, lowered the price target from $28 to $25, which implies upside potential of 3.4% from current levels. The Wall Street community is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 2 Buys and 2 Holds.